Core Viewpoint - Midea Medical's stock rose by 5.79% on September 16, reaching 20.66 yuan per share, with a total market capitalization of 3.434 billion yuan [1] Company Overview - Midea Medical Industrial Equipment Co., Ltd. is located in Yuhuan City, Zhejiang Province, established on March 10, 2003, and listed on December 3, 2019. The company specializes in the research, production, sales, and service of medical consumables and intelligent equipment [1] - The main business revenue composition includes: 42.18% from safe infusion line machines, 37.90% from blood purification line machines, 14.04% from safe infusion single machines, and 5.87% from other categories [1] Fund Holdings - According to data from the top ten heavy stocks of funds, one fund under Guotai Fund holds a significant position in Midea Medical. The Guotai Value Flexible Allocation Mixed Fund (005746) held 200,000 shares in the second quarter, accounting for 1.08% of the fund's net value, ranking as the eighth largest heavy stock [2] - The fund has generated an estimated floating profit of approximately 226,000 yuan today [2] Fund Performance - The Guotai Value Flexible Allocation Mixed Fund (005746) was established on March 27, 2018, with a latest scale of 273 million yuan. Year-to-date returns are 5.47%, ranking 6623 out of 8174 in its category; the one-year return is 10.46%, ranking 6881 out of 7982; and since inception, the return is 46.99% [2] Fund Managers - The fund managers are Cheng Zhou and Cheng Yao. Cheng Zhou has a cumulative tenure of 17 years and 171 days, with a total fund asset scale of 6.594 billion yuan, achieving a best fund return of 361.33% and a worst return of -37% during his tenure [3] - Cheng Yao has a cumulative tenure of 4 years and 71 days, managing a total fund asset scale of 1.921 billion yuan, with a best fund return of 14.74% and a worst return of 3.78% during her tenure [3]

Core Viewpoint - The company is focusing on integrating its contact lens business with CDMO and proprietary brand sales, aiming to develop a multi-brand matrix to capture customer segments. Group 1: Financial Performance - As of June 30, 2025, the company's contract liabilities amounted to 181.57 million yuan, an increase of 83.28% compared to the end of the previous year, indicating a growth in orders that supports the recovery of the main business [2][3]. - The current market capitalization of the company is 3.26 billion yuan, ranking 68th out of 78 in the automation equipment sector and 4346th out of 5153 in the A-share market [1]. Group 2: Product Development - The company is applying for registration of daily disposable soft contact lenses, while the silicone hydrogel products are still in the research and sample preparation stage [2][3]. - The company plans to start with the hydrogel series for its contact lens products and will subsequently develop silicone hydrogel series and functional soft lenses [1]. Group 3: Market Dynamics - The safety infusion equipment segment is currently under pressure due to reduced investment willingness from downstream customers and intensified domestic competition [1][3]. - The blood purification equipment segment is maintaining a growth trend, benefiting from the ongoing domestic replacement of blood dialysis devices [1][3]. - New product categories, including pre-filled series devices and insulin injection pen series devices, are showing positive trends due to the development of biopharmaceuticals, medical aesthetics, and weight-loss drug markets [1].

谈及相较于当前主流美瞳品牌的差异化优势，管理层介绍，公司隐形眼镜业务定位产销一体化，相关隐 形眼镜生产线自己开发制造，能充分发挥迈得20多年设备制造能力优势，可根据产线调试情况、市场反 馈情况等进行快速优化改善设备、优化成本。 9月10日，迈得医疗举办2025半年度业绩说明会。会上有投资者询问，已看到月抛型美瞳产品上线，公 司对于相关业务未来有哪些展望。 此外，公司目前正在申请佩戴周期为日抛的软性亲水接触镜注册证照。硅水凝胶尚处于研发制样阶段。 对此，管理层回应，公司将继续对隐形眼镜业务开展相关材料研发、产品取证、自主品牌上线、新产品 开发、产线优化降本等工作，致力打通隐形眼镜上下游产业链。同时，公司将加大人才引进力度，拓展 材料、光学、文案设计、销售等方面专家的人才引进，开发更多适合市场需求的产品类别，进一步推动 隐形眼镜公司业务的全面发展。 （上证路演） ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2025年9月5日收盘，迈得医疗（688310）报收于21.17元，较上周的19.67元上涨7.63%。本周，迈 得医疗9月5日盘中最高价报21.38元，股价触及近一年最高点。9月3日盘中最低价报19.43元。迈得医疗 当前最新总市值35.19亿元，在自动化设备板块市值排名65/78，在两市A股市值排名4141/5152。 本周关注点 迈得医疗工业设备股份有限公司将于2025年9月10日（星期三）10:00-11:00通过上证路演中心 （https://roadshow.sseinfo.com/）以网络互动方式召开2025年半年度业绩说明会，就公司2025年半年度经 营成果、财务状况等与投资者进行交流。参会人员包括董事长兼总经理林军华、董事会秘书林栋、财务 负责人林君辉及独立董事张颖辉。投资者可于2025年9月3日至9月9日16:00前通过上证路演中心"提问预 征集"栏目或公司邮箱（zq@maiderchina.com）提前提问。说明会期间，投资者可登录上证路演中心在 线参与并提问 ...

Core Insights - The total margin balance of the STAR Market on September 3 was 228.939 billion yuan, a decrease of 1.9 billion yuan from the previous trading day [1] - The financing balance was 228.159 billion yuan, down by 1.892 billion yuan, while the securities lending balance was 0.78 billion yuan, a decrease of 0.08 billion yuan [1] Individual Stock Performance - On September 3, 258 stocks in the STAR Market experienced net financing inflows, with 10 stocks having net inflows exceeding 30 million yuan [1] - Dongxin Technology topped the list with a net financing inflow of 263 million yuan, followed by Baiji Shenzhou, Airo Energy, Yuanjie Technology, and Shijia Photon, all with net inflows exceeding 50 million yuan [1]

Summary of Key Points - On September 3, a total of 33 stocks were identified with institutional activity, with 15 stocks showing net buying and 18 stocks showing net selling [1] - The top three stocks with the highest net buying by institutions were Chenxin Pharmaceutical, Xiaocheng Technology, and Airo Energy, with net buying amounts of 116 million, 111 million, and 72.55 million respectively [1] - The top three stocks with the highest net selling by institutions were Yuanjie Technology, Chengdu Huamei, and Julun Intelligent, with net outflow amounts of 409 million, 112 million, and 98.8 million respectively [1]

Group 1 - On September 3, a total of 33 stocks were involved with institutional investors, with 15 showing net buying and 18 showing net selling [1] - The top three stocks with net buying by institutions were Chenxin Pharmaceutical, Xiaocheng Technology, and Ailuo Energy, with net buying amounts of 116 million, 111 million, and 72.55 million respectively [1][2] - The top three stocks with net selling by institutions were Yuanjie Technology, Chengdu Huamei, and Julun Intelligent, with net outflow amounts of 409 million, 112 million, and 98.8 million respectively [1][3] Group 2 - The stock with the highest net buying was Chenxin Pharmaceutical, which saw a price increase of 10.02% [2] - Xiaocheng Technology experienced a price drop of 3.46% despite a significant net buying amount of 110.9 million [2] - Ailuo Energy had a notable price increase of 19.15% along with a net buying amount of 72.55 million [2] Group 3 - The stock with the highest net selling was Yuanjie Technology, which had a price drop of 13.01% and a net outflow of 409 million [3] - Chengdu Huamei saw a price increase of 14.97% but still experienced a net selling of 112 million [3] - Julun Intelligent had a slight price increase of 0.56% while facing a net outflow of 98.8 million [3]

迈得医疗工业设备股份有限公司 关于召开2025年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025年9月10日（星期三）10:00-11:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688310 证券简称：迈得医疗 公告编号：2025-035 董事长、总经理：林军华先生 董事会秘书：林栋先生 财务负责人：林君辉先生 独立董事：张颖辉女士 会议召开方式：上证路演中心网络互动 投资者可于2025年9月3日（星期三）至9月9日（星期二）16:00前登录上证路演中心网站首页点击"提问 预征集"栏目或通过公司邮箱（zq@maiderchina.com）进行提问。公司将在说明会上对投资者普遍关注 的问题进行回答。 迈得医疗工业设备股份有限公司（以下简称"公司"）已于2025年8月28日发布公司2025年半年度报告， 为便于广大投资者更全面深入地了解公 ...

证券代码：688310 证券简称：迈得医疗 公告编号：2025-035 迈得医疗工业设备股份有限公司 关于召开 2025 年半年度业绩说明会的公告 ?会议召开时间：2025 年 9 月 10 日（星期三）10:00-11:00 ? 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） ?会议召开方式：上证路演中心网络互动 ?投资者可于 2025 年 9 月 3 日（星期三）至 9 月 9 日（星期二）16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （zq@maiderchina.com）进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 迈得医疗工业设备股份有限公司（以下简称"公司"）已于 2025 年 8 月 28 日 发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 9 月 10 日（星期三）10:00-11:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 ...

Core Viewpoint - Maide Medical announced that its 2025 semi-annual performance briefing is scheduled for September 10, 2025 [1] Company Summary - The company is preparing to hold a performance briefing to discuss its financial results for the first half of 2025 [1]